>>> Cabot misses by $0.09, misses on revs

Cabot misses by $0.09, misses on revs

Reports Q3 (Jun) earnings of $0.64 per share, excluding non-recurring items, $0.09 worse than the Capital IQ Consensus Estimate of $0.73; revenues fell 26.2% year/year to $694 mln vs the $774.89 mln consensus.
  • Margin pressure in Reinforcement Materials and lower project activity in Specialty Fluids led to lower earnings year over year
  • Record results for Performance Chemicals
  • Company remains highly focused on managing costs and cash flow.
  • "Looking ahead, we expect the markets for the Performance Chemicals segment to remain strong in both specialty carbons and metal oxides. The outlook for Reinforcement Materials is mixed," Prevost continued, "with strengthening developed economies and sluggish emerging markets. Although the recent Supreme Court decision on MATS has resulted in greater uncertainty for the mercury removal business, we expect that Purification Solutions will continue to operate at current EBITDA run rates in the near term. The Specialty Fluids business continues to work on a broad portfolio of future project options but the short-term outlook remains challenging."

>>> Zoetis beats by $0.05, beats on revs; raises low end of FY15 guidance; reaff

Zoetis beats by $0.05, beats on revs; raises low end of FY15 guidance; reaffirms long term guidance

  • Reports Q2 (Jun) earnings of $0.43 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.38; revenues rose 1.5% year/year to $1.18 bln vs the $1.12 bln consensus.
  • Co issues guidance for FY15, raises EPS to $1.63-1.68, excluding non-recurring items, from $1.61-1.68 vs. $1.66 Capital IQ Consensus; raises FY15 revs to $4.70-4.775 bln from $4.675-1.775 bln vs. $4.74 bln Capital IQ Consensus Estimate.
  • The company also reaffirmed its long-term outlook for 2016 and 2017

>>> Regeneron Pharms beats by $0.11, beats on revs; raises EYLEA US net product

Regeneron Pharms beats by $0.11, beats on revs; raises EYLEA US net product sales guidance

Reports Q2 (Jun) earnings of $2.89 per share, $0.11 better than the Capital IQ Consensus of $2.78; revenues rose 50.0% year/year to $999 mln vs the $887.59 mln consensus.
  • Collaboration revenues in the second quarter of 2015 increased primarily due to higher reimbursement of the Company's research and development expenses under its antibody collaboration with Sanofi and an increase in the Company's net profit from commercialization of EYLEA outside the United States.
  • Net sales of EYLEA in the United States increased 58% to $655 million from $415 million in the second quarter of 2014.
    • Overall distributor inventory levels remained within the Company's one- to two-week targeted range.
  • Co raises EYLEA US net product sales to +45-50% from +30-35%, lowers R&D and SG&A guidance

Reuters- Brazil presents another hurdle in Monsanto's bid for Syngenta



Seed giant Monsanto Co.'s (MON.N) unwanted takeover bid with Switzerland's Syngenta AG (SYNN.VX) would face strong resistance in Brazil should it go forward, farmers and lawyers said, a hurdle that could delay or force major concessions to the $45 billion deal.

Much of the public focus on the move has revolved around potential antitrust questions in the United States and the European Union, but challenges could also likely arise from emerging agricultural powers such as Brazil and China.

In particular Brazil, the second-largest market for Monsanto and Syngenta, is crucial to the future of both companies. As one of the few places in the world with land available to expand farming, Brazil is likely to surpass the United States as the world's top soybean producer in the coming years, while its tropical climate makes it an enormous pesticide consumer.

Brazil's regulator, Cade, could spend up to a year, the maximum time allowed, analyzing any potential deal, said Marcio de Carvalho Silveira Bueno, an antitrust lawyer at Sao Paulo-based TozziniFreire Advogados.

"Cade has seen big cases, but this would be one of the biggest without a doubt," he said.

The Brazil office of Syngenta, which is already showing signs of resisting the takeover, called the idea of resolving antitrust issues by selling the seed business and overlapping chemistry assets "far too simplistic" and said "divesting Syngenta's seeds business would dismantle our integrated strategy in emerging markets such as Brazil."

Monsanto spokeswoman Sara Miller said Monsanto expects "a thorough global regulatory process" but remains confident in its ability "to obtain all necessary global regulatory approvals." Farmers are the company's No. 1 priority, she said in an e-mail.

"It’s impossible to know how far reaching the restrictions would be, but some kind of divestment or other kind of structural remedy will be solicited,” said Antonio Garbelini Junior, partner and antitrust expert at Sao Paulo law firm Siqueira Castro. He noted that all parties affected by the merger would be heard by the regulator.

Brazilian farmers are already opposed to the deal, said Ricardo Tomczyk, president of Brazil's main farmers' lobby Aprosoja in top growing state Mato Grosso. He said the group would closely monitor Cade's evaluation of any merger proposal and didn't rule out additional legal measures.
"It would distort the free market and hurt the sector all around ... we are quite concerned," said Tomczyk, a lawyer who has also represented farmers in legal battles against Monsanto over royalty fees.

He said the farmers' main concerns are with genetically modified seeds, where Monsanto leads and Syngenta is developing technology in Brazil, and agricultural chemicals, where Syngenta is the leader and Monsanto has some production.

Monsanto has committed to divesting all of Syngenta's seeds and traits business, as well as some overlapping chemistry assets.

Ratcheting up the pressure to find a deal, which first came to light in late April, is German chemicals group BASF's (BASFn.DE) bid for Syngenta. BASF has already lined up a loan package from large multinational banks, people familiar with the matter said. [ID:nWEB00OQ8]

"AGRICULTURAL MONSTER"

Independent Brazilian lawyers noted that in recent years Cade has approved some large tie-ups affecting agriculture, one of few bright spots in Brazil's stalled economy, but with restrictions.

It approved the takeover of the country's main railway operator, America Latina Logistica SA, by Cosan Logistica SA in February, addressing sugar and grain producer concerns by requiring third party access to Cosan's two dry bulk terminals at Santos port.

Cade threatened to derail a 2009 merger between Perdigao and Sadia to create processed foods giant Brasil Foods, now known as BRF SA (BRFS3.SA), but ultimately endorsed a plan requiring the latter to sell 80 percent of Perdigao's production capacity and halve the sale of some of its products.
Vinícius de Carvalho, the president of Cade, declined to comment on whether a Monsanto-Syngenta deal would require antitrust remedies.

Syngenta said in a statement to Reuters that combining the two companies would create "an agricultural monster accounting for more than 50 percent of farmers' seed and crop protection input costs in many countries, including Brazil."

Brazil is particularly known for its regulatory scrutiny and said a combined entity would dominate in corn and soybeans, Syngenta added.

"One would expect Cade to scrutinize a proposed combination very, very closely because the combined firm would have tremendous market power," Jon Leibowitz, an attorney for Syngenta at Davis Polk and former Chairman of the Federal Trade Commission in Washington, said in an interview.

The two firms would have high combined shares in glyphosate and in two competing herbicides, he added.

Sources familiar with Monsanto said the company's legal focus so far has been on potential antitrust hurdles in the United States and the EU, but that it has legal teams in Brazil, China and elsewhere studying the merger.

One source said Monsanto doesn't have enough information, especially from Syngenta, to do much of an evaluation in these markets right now.

FT : Survey backs Monsanto’s Syngenta bid

Survey backs Monsanto’s Syngenta bid

Bernstein poll finds investors looking for 5% price rise on $45bn offer

Will the summer standoff continue between US agricultural chemical and seed group Monsanto and its Swiss takeover target Syngenta?

Amid a brief flurry of excitement prompted by prospects of a counter bid, analysts at Bernstein Research also provided a bit of buzz around the $45bn unsolicited offer from the US agri-business group by releasing a poll of its own fund manager clients.

The survey of almost 100 investors, of which two-thirds hold Syngenta shares, showed that more than 90 per cent of the respondents were in favour of negotiation compared to 5 per cent preferring a new strategy.

They also said that they saw an average “acceptable offer price at SFr473” per share, a 5 per cent premium to the current Monsanto offer of SFr449.

The fund managers polled by Bernstein – among whom include at least three top ten investors in the Swiss group – expressed scepticism over Syngenta’s current strategy and targets.

About 75 per cent said the strategy and the company hitting its 2018 earnings before interest, tax, depreciation and amortisation target as “slightly incredible” or “not credible”, with none finding Syngenta’s management “highly credible”.

Jeremy Redenius, analyst at Bernstein behind the survey, said the likely scenarios included shareholders pushing for an extraordinary general meeting, Syngenta seeking a white knight or the Swiss group changing strategy or the management team.

Syngenta has called on Monsanto to increase its offer and also wants the company to raise its existing termination fee proposal of $2bn. The US group, meanwhile, asked the Swiss group to come to the negotiating table.

The investors surveyed by Bernstein seem to back Monsanto’s view, saying the Swiss group’s lack of engagement was “incredible” and “not appropriate.”

But Syngenta says that following its investor roadshow after its half year results recently, it met with over 100 investors in Europe and US and is standing firm.

“It is clear from these conversations that the proposal from Monsanto is wholly unacceptable as it fundamentally undervalues Syngenta’s future prospects and is fraught with significant execution and regulatory risk,” the company says.


One top 20 shareholder says that management is right to hold out for a better offer and not accept the initial bid. He believed that Syngenta’s management would engage as long as Monsanto raised its offer.

After Syngenta’s results presentation last month, Michel Demaré, the group’s chairman told the Financial Times that Syngenta’s top 20 shareholders were divided into two camps – one group that only held the Swiss group’s shares, who were sympathetic to the stand-alone argument, and another group, which owned both Syngenta and Monsanto shares, that wanted the merger to go ahead.

Of the top 20 Syngenta shareholders, only two do not have Monsanto stock. Those who do account for more than a quarter of the Swiss company’s shares, according to Bloomberg data.

As Europe goes into summer holiday mode, Syngenta’s board and management may not have such a relaxing August.

(Manager-Magazin) problems in China bring BMW profit forecast in Danger

Problems in China, which grew stronger rival Mercedes-Benz and higher costs for research and development have stressed the success spoiled carmaker BMW in the second quarter. The problems in China bring the profit forecast in danger.

The new BMW boss Harald Krüger has started with a decline in profits into office. Consolidated earnings before taxes fell in the second quarter by 2.7 percent to 2.58 billion euros, the carmaker said on Tuesday. The share of BMW showing stock market chart then slipped by more than 2 percent and fell to the Dax-end.
More and more dark clouds in the world's biggest car market China cast a shadow on the BMW targets for 2015. "If the challenges in the Chinese market to increase, we can not rule out an impact on our forecast," it says in the semi-annual report of the Group, on Tuesday has been published.

Yield shrinks to 8.4 percent

This therefore also applies to the core Automobiles segment where BMW is still a margin before interest and taxes (EBIT margin), between eight and ten percent. In the second quarter, the margin shrank to 8.4 (previous year: 11.7) per cent. So BMW was behind the competitors Mercedes with 10.7 percent and Audi with 9.9 percent.

The profit contribution from China fell again at BMW. The Munich set around a fifth of all vehicles from the People's Republic. In May, sales went there for the first time in more than a decade back.

Especially Rolls-Royce suffers because the Chinese buy in the face of an economic slowdown, a hard fight against corruption and turmoil in the stock market a few luxury cars. Rival Audi and its parent Volkswagen already screwed because of the weakness in China recently back the sales forecasts. Rival Daimler showing stock market chart shone, however, in the People's Republic.

In China, show an increasing uncertainty about the further development of the economy, it said in the BMW report. In the car market, the dynamics of recent years have subsided, but is compared to Western industrial nations "still relatively high". For the global auto markets expect BMW stock market chart showing a growth in 2015 of only 1.1 percent.

But because the Munich want to increase sales thanks to numerous new and revised models this year clear, they reaffirmed their forecast, according to which the consolidated net profit is expected to grow solidly before taxes. In the second quarter, he sagged by nearly three percent.

BMW-core division cuts underperformed

The disappointment of investors is likely to be due to the surprisingly weak performance of the core division:
In the core division Automobiles BMW disappointed expectations: Here shrank the profit before interest and taxes (EBIT) by 15.8 percent to 1.82 billion euros. To book the cooling suggested in the important sales market of China, the contribution to earnings from there dropped. In addition, the Munich-selling more small and compact vehicles, which yield less.

"Revenue falls much better than expected, the result is only in line with expectations. The correspondingly disappointing margin expressed on the price," said expert Frank Schneider from Alpha Securities Trading figures. In the car business profits have even missed expectations.

Tailwind BMW hopes of new models. The new 7 Series, the flagship of the group, comes in the fall on the market. BMW has since the beginning of 3200 created more points and now employs around 119,500 employees worldwide.

(BFW) Philips Said to Work With BofA on Medical Deals

Royal Philips NV is working with Bank of America Corp. as it scouts for acquisitions in medical devices to expand its health-care division, according to people with knowledge of the matter.
While the process is preliminary and no specific targets have been identified, Philips would consider smaller acquisitions as well as multibillion-euro deals over the next six to 12 months, said the people, who asked not to be identified because the plans are private.
The budget for purchases may increase depending on other potential asset disposals, the people said. The company also could use the proceeds from an initial public offering or sale of its lighting division. Philips is reviewing options for that business, which it plans to sell as soon as next year.
Philips is eyeing medical-device companies in areas such as radiotherapy, imaging and home care both in the U.S. and in Europe, the people said. In December, Philips agreed to buy Volcano Corp. for $1.2 billion to expand in catheter-based imaging of the heart and blood vessels as part of a wider refocus on more profitable markets such as medical gear.
Bank of America’s Merrill Lynch unit will advise on everything from takeovers to strategy for the medical division while Philips is hiring different advisers for the separation of the lighting unit, the people said.
A spokesman for Amsterdam-based Philips declined to comment, as did a Bank of America spokeswoman.
On July 27, Philips reported surging demand at its North American medical business, bolstering Chief Executive Officer Frans van Houten’s plan to split the 124-year-old company in two to focus on health care. Van Houten is counting on demand for technology that allows hospitals to analyze clinical data and patients to monitor health and nutrition on smartphones.

BFW 08/04 08:55 *PHILIPS SAID TO WORK WITH BANK OF AMERICA ON MEDICAL DEALS

Philips Said to Work With BofA on Medical Deals
2015-08-04 08:56:28.754 GMT


By Manuel Baigorri and Aaron Kirchfeld
(Bloomberg) -- Philips is scouting for acquisitions in
medical devices to expand its health-care division, according to
people with knowledge of the matter who asked not to be
identified because the plans are private.

* Process is preliminary and no specific targets have been
identified
* Philips would consider smaller acquisitions as well as
multibillion-euro deals over the next 6-12 mos.
* Budget for purchases may increase depending on other
potential asset disposals
Link to full story

For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Andrew Rummer in London at +44-20-3525-3722 or
arummer@bloomberg.net
To contact the editor responsible for this story:
Kevin Reynolds at +1-212-617-8950 or
kreynolds@bloomberg.net

(BofA-ML) European Sector Signals : Aug 2015


* Holding on to domestics while avoiding EM cyclicals
Last month’s sector performances were biased against any form of EM exposure. However,
along with defensives, domestic-exposed cyclicals (Construction and Financials)
outperformed. We see ‘bullish signals’ for these sectors – all five of the Sector Signal longs
are unchanged from last month. ‘Bullish’ sectors returned +3.3% on average, while ‘bearish’
sectors returned +2.8%. Broadly speaking, we are more bullish on European exposure and
have ‘bearish signals’ on EM-exposed/defensive sectors.

* Selectively contrarian for commodity-plays
Based on our Fund Manager Survey, the most contrarian of contrarians would be buying into
the collapsing commodity cycle. However, we are still negative on Basic Resources, despite
our tactical preference for the least-crowded sectors. Earnings revision trends imply further
downside for the sector - unlike Oil & Gas, where revisions are supportive. Less
‘controversial’ contrarian ideas include long Construction and long Banks.

* Avoid all defensive sectors
Macro recovery in Europe implies relative underperformance of Food & Bev and Healthcare,
despite strong momentum on oil price weakness. In addition, earnings revisions for these
sectors are poor, while sentiment remains stretched – especially for Healthcare. We believe
our top strategic recommendation of Financials over Staples remains tactically attractive.

* What is Sector Signals?
'Sector Signals’ combines three of our flagship products, along with price momentum, to
provide ‘Bullish’ and ‘Bearish’ signals to time entry points in European sectors. Components
that form the framework are: 1) Macro: ‘Style Cycle’ determines the beta exposure 2)
Earnings: EPS Revision Ratio (ERR) 3) Positioning: Using inputs from our Fund Manager
Survey (FMS) to avoid crowded positions and find opportunities in uncrowded places and 4)
Price Momentum.